browse Browse

pac.dog pac.dog / CRS reports

R45948 — The Controlled Substances Act (CSA): A Legal Overview for the 119th Congress

Reports · published 2025-01-22 · v6 · Active · crsreports.congress.gov ↗

Read
HTML · PDF
Authors
Joanna R. Lampe
Report id
R45948
Summary

The Controlled Substances Act (CSA) establishes a unified legal framework to regulate certain drugs and other substances that are deemed to pose a risk of abuse and dependence. The CSA may apply to drugs that are medical or recreational, legally or illicitly distributed, but the statute does not apply to all drugs. Rather, it applies to drugs and other substances that have been designated for control by Congress or through administrative proceedings. The CSA also applies to controlled substance analogues that are intended to mimic the effects of controlled substances and to certain listed chemicals—chemicals commonly used to manufacture controlled substances. Controlled substances subject to the CSA are divided into categories known as Schedules I through V based on their medical utility and their potential for abuse and dependence. Substances considered to pose the greatest risk to the public health and safety are subject to the most stringent controls and sanctions. A lower schedule number corresponds to greater restrictions, so substances in Schedule I are subject to the strictest controls, while substances in Schedule V are subject to the least strict. Many substances regulated under the CSA are also subject to other federal or state regulations, including the Federal Food, Drug, and Cosmetic Act. The Drug Enforcement Administration (DEA) is the federal agency primarily responsible for implementing and enforcing the CSA. DEA may designate a substance for control through notice-and-comment rulemaking if the substance satisfies the applicable statutory criteria or may undertake such rulemaking to alter or remove existing controls on a controlled substance. The agency may also place a substance under temporary control on an emergency basis if the substance poses an imminent hazard to public safety. In addition, DEA may designate a substance for control if required by the United States’ international treaty obligations. In the alternative, Congress may place a substance under control or modify or remove controls by statute. The CSA aims to ensure that patients have access to pharmaceutical controlled substances for legitimate medical purposes while also seeking to protect public health from the dangers of controlled substances diverted into or produced for the illicit market. To accomplish those two goals, the statute creates two overlapping legal schemes. Registration provisions require entities working with controlled substances to register with DEA and take various steps to prevent diversion and misuse of controlled substances. Trafficking provisions establish penalties for the production, distribution, and possession of controlled substances outside the legitimate scope of the registration system. DEA is primarily responsible for enforcing the CSA’s registration provisions and works with the Criminal Division of the Department of Justice to enforce the Act’s trafficking provisions. Violations of the registration provisions generally are not criminal offenses, but certain serious violations may result in criminal prosecutions yielding fines and even short prison sentences. Violations of the trafficking provisions are criminal offenses that may result in large fines and lengthy prison sentences. During the 117th and 118th Congresses, significant legal developments related to controlled substances regulation occurred via executive branch actions, court decisions, and enacted federal and state legislation. Some Members of Congress also introduced a number of proposals to amend the CSA in various ways. Recent years saw developments in marijuana law and policy, including a growing divergence between federal and state marijuana laws, a 2022 presidential grant of clemency for federal and D.C. marijuana possession offenses, and 2024 DEA rulemaking proceedings proposing to reschedule marijuana under the CSA. Some Members of the 118th Congress reintroduced legislation such as the MORE Act (H.R. 5601) and the Cannabis Administration and Opportunity Act (S. 4226), both of which would have removed marijuana from control under the CSA. Some Members also introduced other bills that would have addressed specific aspects of the divergence between federal and state marijuana law, including proposals seeking to facilitate clinical research involving marijuana and other Schedule I controlled substances. In addition, the 118th Congress confronted ongoing issues related to the opioid epidemic, including the regulation of the powerful opioid fentanyl and its analogues. Some Members of Congress also considered whether to impose controls on xylazine, an unscheduled veterinary sedative that is sometimes used by humans alone or in combination with controlled substances.

Bills cited (47)

Curated by CRS — every bill listed in this report's relatedMaterials. Edge type cited_in_report, gold confidence.

pac.dog is a free, independent, non-partisan research tool. Every candidate, committee, bill, vote, member, and nonprofit on this site is mirrored from primary U.S. government sources (FEC, congress.gov, govinfo.gov, IRS) and each state's Secretary of State / election commission — no third-party data vendors, no paywall, no editorial intermediation. Citations to the originating source are on every detail page.